Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats

被引:53
作者
Breuer, Megan E.
Groenink, Lucianne
Oosting, Ronald S.
Westenberg, Herman G. M.
Olivier, Berend
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Psychopharmacol, NL-3584 CA Utrecht, Netherlands
[2] Rudolf Magnus Inst Neurosci, Dept Pharmacol & Anat, Sect Behav Genom, NL-3508 TA Utrecht, Netherlands
[3] Univ Utrecht, Med Ctr, Dept Psychiat, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands
[4] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
关键词
cessation of treatment; depression; escitalopram; imipramine; olfactory bulbectomy; open field;
D O I
10.1016/j.biopsych.2006.08.032
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Olfactory bulbectomy (OBX) in rats causes several behavioral and neurochemical central nervous system changes, reminiscent of symptoms of human depression. Moreover, depression-like behavior after OBX can be reversed with antidepressant drugs. However, the lasting effects of these antidepressant drugs on behavior after cessation of treatment have never been studied. Methods: Male rats received OBX or sham surgery. After recovery, animals received 14 consecutive daily doses of imipramine (20 mg/kg), escitalopram (5 and 10 mg/kg), or vehicle. Animals were tested in an open field after acute, sub-chronic, and chronic injections, as well as 1, 2, 6, and 10 weeks after cessation of treatment. Results: The OBX-induced hyperactivity was normalized after sub-chronic administration of imipramine and escitalopram. Two weeks after treatment, activity of OBX animals was comparable to sham-treated animals, but after 6 weeks, OBX animals treated with both doses of escitalopram had returned to pre-treatment hyperactivity levels. The OBX animals treated with the high imipramine dose (20 mg/kg) retained activity levels comparable to sham-treated animals until 10 weeks after cessation of treatment. Conclusions: Chronic but not acute administration of imipramine and escitalopram normalizes OBX-induced hyperactivity. This effect continues for up to 10 weeks after cessation of treatment in a dose dependant manner.
引用
收藏
页码:990 / 995
页数:6
相关论文
共 42 条
[1]   The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study [J].
Aydemir, O ;
Deveci, A ;
Taneli, F .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (02) :261-265
[2]   Quetiapine and venlafaxine synergically regulate heme oxygenase-2 protein expression in the hippocampus of stressed rats [J].
Chen, Z ;
Xu, HY ;
Haimano, S ;
Li, XK ;
Li, XM .
NEUROSCIENCE LETTERS, 2005, 389 (03) :173-177
[3]   Bi-phasic change in BDNF gene expression following antidepressant drug treatment [J].
Coppell, AL ;
Pei, Q ;
Zetterström, TSC .
NEUROPHARMACOLOGY, 2003, 44 (07) :903-910
[4]   Assessing antidepressant activity in rodents: recent developments and future needs [J].
Cryan, JF ;
Markou, A ;
Lucki, I .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (05) :238-245
[5]   What should animal models of depression model? [J].
Frazer, A ;
Morilak, DA .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2005, 29 (4-5) :515-523
[6]   Influence of olfactory bulbectomy and subsequent imipramine treatment on 5-hydroxytryptaminergic presynapses in the rat frontal cortex:: behavioural correlates [J].
Grecksch, G ;
Zhou, D ;
Franke, C ;
Schröder, U ;
Sabel, B ;
Becker, A ;
Huether, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (08) :1725-1731
[7]   Major depression is not a diagnosis, it is a departure point to differential diagnosis - clinical and hormonal considerations (A commentary and elaboration on Antonejevic's paper) [J].
Halbreich, U .
PSYCHONEUROENDOCRINOLOGY, 2006, 31 (01) :16-22
[8]   Critical role of brain-derived neurotrophic factor in mood disorders [J].
Hashimoto, K ;
Shimizu, E ;
Iyo, M .
BRAIN RESEARCH REVIEWS, 2004, 45 (02) :104-114
[9]   CHANGES IN NEUROTRANSMITTER METABOLISM FOLLOWING OLFACTORY BULBECTOMY IN THE RAT [J].
JANCSAR, SM ;
LEONARD, BE .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1984, 8 (02) :263-269
[10]   BDNF variation and mood disorders:: A novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects [J].
Jiang, XY ;
Xu, K ;
Hoberman, J ;
Tian, F ;
Marko, AJ ;
Waheed, JF ;
Harris, CR ;
Marini, AM ;
Enoch, MA ;
Lipsky, RH .
NEUROPSYCHOPHARMACOLOGY, 2005, 30 (07) :1353-1361